Dat geeft het liquidatie team van srne de tijd om die stock dividend (deels) terug te eisen.
Details kan je op stretto lezen.
2 van de 3 dividend aandelen terug geven of 1dollar betalen per div aandeel.
✅ Sluit aan bij hét beursforum van de Benelux!
Minder advertenties, abonneer gratis op favoriete onderwerpen, chat mee, stel vragen en deel kennis. Naast unieke functies op het forum staan wij ook voor inhoudelijke en respectvolle omgang. In 1 minuut bent u aangemeld!
Scilex (SCLX)
-
Bertje
- Forumveteraan
- Berichten: 1437
- Lid geworden op: 13 dec 2021 23:30
- Heeft bedankt: 186 maal
- Is bedankt: 664 maal
Re: Scilex (SCLX)
krijgen we een ontploffing vandaag.
Scilex Holding Company (SCLX) : 0.8080+0.0212 (+2.6945%) premarket: 0.92 + 0.112 (+13.84%)
52 Week Range 0.7320 - 2.6300
Market Cap (intraday) 108.21M
Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential
Scilex Holding Company
Wed, Oct 16, 2024, 1:00 PM
Scilex Holding Company
• Scilex Holding Company seeks to maximize the value of its stockholders, including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals (“Scilex Pharma”) in markets and on securities exchanges in or outside of the U.S., including Hong Kong.
• Scilex Holding Company management believes the potential value of Scilex Pharma may exceed the current valuation of its parent company, Scilex Holding Company, and that a potential spinoff or public listing of Scilex Pharma would serve to unlock the potential value of Scilex Pharma and its parent, Scilex Holding Company. Also a potential strategic transaction and/or dividend of Scilex Pharma common stock to Scilex Holding Company stockholders.
• Scilex Pharma has three FDA-approved commercial products in the market and 3X version follow-on product, SP-103, for the next generation of ZTlido®:
o ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain with an average of 50% growth in gross sales for the past two years, estimated to exceed $180 million gross sales in 2024.
o ZTlido® is expected to be distributed outside of the U.S. in 2025 with exclusive territory distributors in the Middle East and North/South Africa countries with a $105 million minimum 5 year purchase commitment.
o ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size was estimated to be $1.8 billion in 2022.2
o ELYXYB® filed a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of for acute treatment of migraine with or without aura in Canada.
The anticipated timeline for approval in Canada is expected to be Q1-2025.
According to market data from 2018, it was found that migraine was more severe than other types of headaches and it is estimated to have impacted more than 2.7 million Canadians with the Canadian migraine therapeutics market estimated to reach approximately $400 million by 2025.3
o Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States4. The gout treatment market is projected to reach $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.5
o SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain. It is estimated that the U.S. low back and neck pain market will reach $134.5 billion.6 Based on the independent market research conducted by Syneos Health Consulting (“Syneos”), with the substantial intent in utilization for SP-103 with peak sales potential projected to reach $1.2 billion annually in the 6th year post launch.
PALO ALTO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its board of directors has authorized management to explore ways to maximize the value of its wholly owned subsidiary, Scilex Pharma, including by way of conducting a spinoff or public listing of securities of Scilex Pharma in markets and on securities exchanges outside of the U.S., including Hong Kong, and/or a potential strategic transaction or dividend of Scilex Pharma common stock to Scilex stockholders.
Scilex Pharma launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (“ZTlido”), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. In 2023, ZTlido® was recognized as the most prescribed non-opioid branded pain treatment by pain specialists, according to Prescription Data from Symphony Health and ZTlido® profile being viewed as a leading prescription lidocaine patch by pain specialists. Based on the independent market research conducted by Syneos Health Consulting (“Syneos”), with the new campaign, health care providers (HCPs) report increased awareness and substantial intent to utilize for ZTlido® with peak sales potential projected to reach over $500 million in the next 6 years in the U.S. In June 2022, Scilex Pharma in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (“GLOPERBA”), a U.S. Food and Drug Administration (“FDA”)-approved prophylactic treatment for painful gout flares in adults, in the United States of America (“U.S.” or the “United States”). In February 2023, Scilex Pharma acquired the rights related to ELYXYB (celecoxib oral solution) (“ELYXYB”) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Scilex Pharma launched ELYXYB in the U.S. in April 2023 and commercialized GLOPERBA in the U.S. in June 2024.
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion
Scilex Holding Company
Wed, Oct 16, 2024, 10:00 AM
Scilex Holding Company
• Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the “Business Combination”) with Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”).
• Based on an independent market research conducted by Syneos Health Consulting (“Syneos”), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.
• Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) announced that it anticipates the filing of a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) before the end of October 2024 for the previously announced proposed Business Combination with Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”), which provides for a pre-transaction equity value of Semnur of $2.5 billion.
• The closing of the Business Combination is expected to occur by the end of fourth quarter of 2024 or the first quarter of 2025.
• As previously disclosed, the Board of Directors of Scilex approved a resolution to authorize a potential dividend of up to 10% of Scilex’s ownership interest in Semnur to Scilex shareholders, subject to registration statement of Semnur on file with the SEC. These shares will be freely tradable upon exchanging to Denali common shares after Business Combination.
• Scilex will set a record date for the dividend shares after Semnur registration statement on file with SEC.
PALO ALTO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it anticipates the filing of the Registration Statement with the SEC before the end of October 2024 relating to the previously announced proposed Business Combination with Denali Capital Acquisition Corp. (Nasdaq: DECA) for a pre-transaction equity value of $2.5 billion which transaction is expected to occur by the end of fourth quarter of 2024 or the first quarter of 2025.
Scilex Holding Company (SCLX) : 0.8080+0.0212 (+2.6945%) premarket: 0.92 + 0.112 (+13.84%)
52 Week Range 0.7320 - 2.6300
Market Cap (intraday) 108.21M
Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential
Scilex Holding Company
Wed, Oct 16, 2024, 1:00 PM
Scilex Holding Company
• Scilex Holding Company seeks to maximize the value of its stockholders, including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals (“Scilex Pharma”) in markets and on securities exchanges in or outside of the U.S., including Hong Kong.
• Scilex Holding Company management believes the potential value of Scilex Pharma may exceed the current valuation of its parent company, Scilex Holding Company, and that a potential spinoff or public listing of Scilex Pharma would serve to unlock the potential value of Scilex Pharma and its parent, Scilex Holding Company. Also a potential strategic transaction and/or dividend of Scilex Pharma common stock to Scilex Holding Company stockholders.
• Scilex Pharma has three FDA-approved commercial products in the market and 3X version follow-on product, SP-103, for the next generation of ZTlido®:
o ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain with an average of 50% growth in gross sales for the past two years, estimated to exceed $180 million gross sales in 2024.
o ZTlido® is expected to be distributed outside of the U.S. in 2025 with exclusive territory distributors in the Middle East and North/South Africa countries with a $105 million minimum 5 year purchase commitment.
o ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size was estimated to be $1.8 billion in 2022.2
o ELYXYB® filed a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of for acute treatment of migraine with or without aura in Canada.
The anticipated timeline for approval in Canada is expected to be Q1-2025.
According to market data from 2018, it was found that migraine was more severe than other types of headaches and it is estimated to have impacted more than 2.7 million Canadians with the Canadian migraine therapeutics market estimated to reach approximately $400 million by 2025.3
o Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States4. The gout treatment market is projected to reach $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.5
o SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain. It is estimated that the U.S. low back and neck pain market will reach $134.5 billion.6 Based on the independent market research conducted by Syneos Health Consulting (“Syneos”), with the substantial intent in utilization for SP-103 with peak sales potential projected to reach $1.2 billion annually in the 6th year post launch.
PALO ALTO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its board of directors has authorized management to explore ways to maximize the value of its wholly owned subsidiary, Scilex Pharma, including by way of conducting a spinoff or public listing of securities of Scilex Pharma in markets and on securities exchanges outside of the U.S., including Hong Kong, and/or a potential strategic transaction or dividend of Scilex Pharma common stock to Scilex stockholders.
Scilex Pharma launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (“ZTlido”), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. In 2023, ZTlido® was recognized as the most prescribed non-opioid branded pain treatment by pain specialists, according to Prescription Data from Symphony Health and ZTlido® profile being viewed as a leading prescription lidocaine patch by pain specialists. Based on the independent market research conducted by Syneos Health Consulting (“Syneos”), with the new campaign, health care providers (HCPs) report increased awareness and substantial intent to utilize for ZTlido® with peak sales potential projected to reach over $500 million in the next 6 years in the U.S. In June 2022, Scilex Pharma in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (“GLOPERBA”), a U.S. Food and Drug Administration (“FDA”)-approved prophylactic treatment for painful gout flares in adults, in the United States of America (“U.S.” or the “United States”). In February 2023, Scilex Pharma acquired the rights related to ELYXYB (celecoxib oral solution) (“ELYXYB”) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Scilex Pharma launched ELYXYB in the U.S. in April 2023 and commercialized GLOPERBA in the U.S. in June 2024.
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion
Scilex Holding Company
Wed, Oct 16, 2024, 10:00 AM
Scilex Holding Company
• Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the “Business Combination”) with Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”).
• Based on an independent market research conducted by Syneos Health Consulting (“Syneos”), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.
• Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) announced that it anticipates the filing of a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) before the end of October 2024 for the previously announced proposed Business Combination with Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”), which provides for a pre-transaction equity value of Semnur of $2.5 billion.
• The closing of the Business Combination is expected to occur by the end of fourth quarter of 2024 or the first quarter of 2025.
• As previously disclosed, the Board of Directors of Scilex approved a resolution to authorize a potential dividend of up to 10% of Scilex’s ownership interest in Semnur to Scilex shareholders, subject to registration statement of Semnur on file with the SEC. These shares will be freely tradable upon exchanging to Denali common shares after Business Combination.
• Scilex will set a record date for the dividend shares after Semnur registration statement on file with SEC.
PALO ALTO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it anticipates the filing of the Registration Statement with the SEC before the end of October 2024 relating to the previously announced proposed Business Combination with Denali Capital Acquisition Corp. (Nasdaq: DECA) for a pre-transaction equity value of $2.5 billion which transaction is expected to occur by the end of fourth quarter of 2024 or the first quarter of 2025.
-
Bertje
- Forumveteraan
- Berichten: 1437
- Lid geworden op: 13 dec 2021 23:30
- Heeft bedankt: 186 maal
- Is bedankt: 664 maal
Re: Scilex (SCLX)
sclx de laatste dagen wel zeer hard achteruit, maar achteruitgang is al jaren bezig...
4,67 Wijziging (-1,35) -22,43%
Apr 17, 2025 6.320
Apr 16, 2025 7.190
Apr 15, 2025 7.640
Apr 14, 2025 7.315
Apr 11, 2025 7.332
Apr 10, 2025 9.450
Apr 09, 2025 10.150
Apr 08, 2025 9.079
Apr 07, 2025 9.233
Apr 04, 2025 9.931
Apr 03, 2025 10.486
Apr 02, 2025 11.585
Op 14 juni 2023 stonden ze 290.500 toen waren er 4.19 miljoen aandelen = meer dan 1.2 miljard...
op 17 juni 2024 stonden ze 80.500, als we kijken naar het aantal aandelen toen dan had het bedrijf een waarde van 416 miljoen.
vandaag amper meer dan 30 miljoen...
Hebben die enorme shortposities gezorgd voor een veel te hoge shortsqueeze naar 1.2 miljard of hebben de shorters dit aandeel kapot gemaakt dat het maar 30 miljoen meer waard is???
4,67 Wijziging (-1,35) -22,43%
Apr 17, 2025 6.320
Apr 16, 2025 7.190
Apr 15, 2025 7.640
Apr 14, 2025 7.315
Apr 11, 2025 7.332
Apr 10, 2025 9.450
Apr 09, 2025 10.150
Apr 08, 2025 9.079
Apr 07, 2025 9.233
Apr 04, 2025 9.931
Apr 03, 2025 10.486
Apr 02, 2025 11.585
Op 14 juni 2023 stonden ze 290.500 toen waren er 4.19 miljoen aandelen = meer dan 1.2 miljard...
op 17 juni 2024 stonden ze 80.500, als we kijken naar het aantal aandelen toen dan had het bedrijf een waarde van 416 miljoen.
vandaag amper meer dan 30 miljoen...
Hebben die enorme shortposities gezorgd voor een veel te hoge shortsqueeze naar 1.2 miljard of hebben de shorters dit aandeel kapot gemaakt dat het maar 30 miljoen meer waard is???
-
manu47
- Regelmatige poster
- Berichten: 272
- Lid geworden op: 10 dec 2021 08:59
- Heeft bedankt: 130 maal
- Is bedankt: 217 maal
Re: Scilex (SCLX)
De "dividendaandelen" die de aandeelhouders van Sorrento hadden gekregen sinds vorige week ook verdwenen uit mijn account via een stock split. Verkoop 14 @ 0 USD, koop 0 @ 0 USD 
. Gelukkige ooit helft aan het dubbel verkocht dus geen verlies aan gemaakt maar wat een nachtmerrie dit 
. Gelukkige ooit helft aan het dubbel verkocht dus geen verlies aan gemaakt maar wat een nachtmerrie dit 71% ETF:C50,CP9,LCUJ,MEUD,SGLD,SXRW,IWDA,SXR8,ICHN,MTPI,QDV5,IBCJ,IUSN,XMLC,OMXH25,WVAL,SMH,WTAI,D5BH
20% Value:AGS,APT,BGFV,BCC,BPOST,1113,CLIQ,ECONB,EVS,FKWL,HEIJ,IAG,KBCA,LOG,MOUR,MYH,BNB,NN,PROX,QIWI
8% Obligatie:ITA21/26,RUM15/35
2% Casino
20% Value:AGS,APT,BGFV,BCC,BPOST,1113,CLIQ,ECONB,EVS,FKWL,HEIJ,IAG,KBCA,LOG,MOUR,MYH,BNB,NN,PROX,QIWI
8% Obligatie:ITA21/26,RUM15/35
2% Casino
-
Bertje
- Forumveteraan
- Berichten: 1437
- Lid geworden op: 13 dec 2021 23:30
- Heeft bedankt: 186 maal
- Is bedankt: 664 maal
Re: Scilex (SCLX)
Waren die niet voor een enorm bedrag teruggekocht?manu47 schreef: ↑21 apr 2025 20:39 De "dividendaandelen" die de aandeelhouders van Sorrento hadden gekregen sinds vorige week ook verdwenen uit mijn account via een stock split. Verkoop 14 @ 0 USD, koop 0 @ 0 USD
Scilex moet Sorrento 145 miljoen betalen (alle kosten inbegrepen) voor hun eigen aandelen, blijkbaar gaat het om 59,726,737 aandelen.
145 miljoen voor 59.726.737 : 35 = (kwam op 85 dollar per aandeel met de huidige omruiling als de deal doorging.)
-
Jack
- Beginnende poster
- Berichten: 79
- Lid geworden op: 16 dec 2021 14:25
- Heeft bedankt: 19 maal
- Is bedankt: 28 maal
Re: Scilex (SCLX)
Ik heb 5,17 euro voor een corporate actie moeten betalen bij Bolero en Scilex is nu een actief aandeel geworden en niet meer grijs. Leuke kost voor mijn volle 9,89 euro aandelen.
Sorrento wel nog altijd grijs.
Sorrento wel nog altijd grijs.
-
Bertje
- Forumveteraan
- Berichten: 1437
- Lid geworden op: 13 dec 2021 23:30
- Heeft bedankt: 186 maal
- Is bedankt: 664 maal
Re: Scilex (SCLX)
Hoelang zullen al die kleine aandeelhouders hun gratis dividend aandelen nog blijven dumpen??
Eind 2023 waren er 4.51 miljoen aandelen, hoogste koers daarna 92.05 = 415 miljoen,
6 maanden later waren er 5.18 miljoen aandelen, hoogste koers 78.05 = 404 miljoen,
momenteel 6.95 miljoen aandelen = 28 miljoen.
Eind 2023 waren er 4.51 miljoen aandelen, hoogste koers daarna 92.05 = 415 miljoen,
6 maanden later waren er 5.18 miljoen aandelen, hoogste koers 78.05 = 404 miljoen,
momenteel 6.95 miljoen aandelen = 28 miljoen.
-
-
Laatste reacties
-
-
- Ga naar laatste bericht Meerwaardebelasting / solidariteitsbijdrage op ...
- Ga naar laatste bericht Mopkes
- Ga naar laatste bericht Opmerkelijk nieuws
- Ga naar laatste bericht Handelsoorlog
- Ga naar laatste bericht Politiek (Europa)
- Ga naar laatste bericht Pfizer (PFE)
- Ga naar laatste bericht Politiek (internationaal)
- Ga naar laatste bericht Politiek (België)
- Ga naar laatste bericht Beurs vandaag / laatste beursnieuws
- Ga naar laatste bericht Metalcorner